Mankind Pharma, BDR Pharma partner for COVID drug Baricitinib in India
New Delhi: Mankind Pharma has recently announced that the company has partnered with BDR Pharmaceuticals International Pvt. Ltd for distributing the Anti-COVID19 drug Baricitinib under the trademark BARIKIND that received restricted emergency use approval, for use in combination with remdesivir.
According to the partnership, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary license from Eli Lilly and Company and Mankind Pharma will be distributing the same.
Read also: Mankind Pharma launches Dapagliflozin brand Justoza for diabetes, heart failure, CKD
Mankind Pharma is the fourth largest pharmaceutical company in India headquartered in New Delhi, India.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd